GB1417323A - Physiologically active xanthine compounds and compositions containing them - Google Patents

Physiologically active xanthine compounds and compositions containing them

Info

Publication number
GB1417323A
GB1417323A GB673173A GB673173A GB1417323A GB 1417323 A GB1417323 A GB 1417323A GB 673173 A GB673173 A GB 673173A GB 673173 A GB673173 A GB 673173A GB 1417323 A GB1417323 A GB 1417323A
Authority
GB
United Kingdom
Prior art keywords
feb
compositions
compositions containing
physiologically active
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB673173A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19681810705 external-priority patent/DE1810705C3/en
Priority claimed from DE2207860A external-priority patent/DE2207860A1/en
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of GB1417323A publication Critical patent/GB1417323A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1417323 Medicines comprising xanthines HOECHST AG 12 Feb 1973 [15 Feb 1972 19 Feb 1972] 6731/73 Heading A5B [Also in Division C2] Theropeutic compositions for treating diseases involving insufficiency of cerebral blood flow comprise compounds of formula or a physiologically acceptable acid addition salt therof, wherein one of R 1 and R 2 is an unbranched hydroxyalkyl group having from 4 to 8 carbon atoms wherein the carbon atom bearing the hydroxyl group is separated from the nearest ring carbon atom by at least 3 carbon atoms and the other is methyl. The compositions may be administered orally, perentarally or rectally and may contain other active ingredients such as vitamins B 1 and B 2 .
GB673173A 1968-11-25 1973-02-12 Physiologically active xanthine compounds and compositions containing them Expired GB1417323A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19681810705 DE1810705C3 (en) 1968-11-25 1968-11-25 Stabilization of vitamins
DE2207860A DE2207860A1 (en) 1972-02-19 1972-02-19 N-hydroxyalkyl theophyllines and theobromines - for improving cerebral irrigation

Publications (1)

Publication Number Publication Date
GB1417323A true GB1417323A (en) 1975-12-10

Family

ID=25756472

Family Applications (1)

Application Number Title Priority Date Filing Date
GB673173A Expired GB1417323A (en) 1968-11-25 1973-02-12 Physiologically active xanthine compounds and compositions containing them

Country Status (2)

Country Link
FR (1) FR2181717B1 (en)
GB (1) GB1417323A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227356A2 (en) * 1985-12-04 1987-07-01 CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. The use of depogen in the treatment of restricted blood circulation
EP0267676A2 (en) * 1986-09-11 1988-05-18 Beecham Wuelfing GmbH & Co KG Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1211333A (en) * 1955-10-19 1960-03-15 Boehringer Sohn Ingelheim Improvements in processes for manufacturing oxyalkylxanthines

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227356A2 (en) * 1985-12-04 1987-07-01 CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. The use of depogen in the treatment of restricted blood circulation
EP0227356A3 (en) * 1985-12-04 1989-12-13 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. The use of depogen in the treatment of restricted blood circulation
EP0267676A2 (en) * 1986-09-11 1988-05-18 Beecham Wuelfing GmbH & Co KG Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases
EP0267676A3 (en) * 1986-09-11 1990-04-04 Beecham Wuelfing GmbH & Co KG Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases

Also Published As

Publication number Publication date
FR2181717A1 (en) 1973-12-07
FR2181717B1 (en) 1976-11-05
AU5220073A (en) 1974-09-19

Similar Documents

Publication Publication Date Title
BE853086A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING, AS ACTIVE INGREDIENTS, TRIAZOLO-PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF PSORIASIS
PT66789A (en) Process for the preparation of pharmaceutical compositions having high rate of resorption,from heart glicosides,in se hardly resorptive,to be parenterically administered
ES460098A1 (en) Derivatives of penicillanic acid
GB1480836A (en) Physiologically active xanthine derivatives and compositions containing them
ES8400417A1 (en) Benzothiazolesulfonamide derivatives, their preparation and ophthalmic compositions containing said derivatives.
GB1417323A (en) Physiologically active xanthine compounds and compositions containing them
US3777020A (en) Psoriasis treatment with mycophenolic acid
KR890007740A (en) Pharmaceutical composition
ES473534A1 (en) Analogues of prostacycline, methods for their preparation and their use in the treatment of circulatory diseases.
GB1252286A (en)
HEJTMANCIK et al. A clinical study of gitalin
ES482742A1 (en) Substituted 2-phenylamino-imidazolines-(2), their acid addition salts, medicaments containing them and processes for their preparation.
GB1145623A (en) Pharmaceutical composition
GB1500300A (en) Pharmaceutical preparation for the treatment of circulatory disorders
ES342394A1 (en) Novel Benzylaminoimidazoline Derivatives, the preparation thereof and Compositions containing the same
IL37656A0 (en) Method and compositions for combatting marek's disease in poultry by the use of diphenyl sulfones and related compounds
GB1270831A (en) Di-hydro triazine derivatives and processes for their manufacture
GB1352392A (en) Phenylisopropylamine derivatives
GB1188434A (en) Guanidine Derivatives and their preparation
GB1356489A (en) Compositions for and method of combating coccidiosis and mareks disease in poultry
GB1342643A (en) Thioacetanilide derivatives
GB1254125A (en) Pharmaceutical composition suitable for the treatment of certain vascular diseases
GB1279380A (en) Improvements in or relating to hydantoins and compositions thereof
GB1287433A (en) Pharmaceutical compositions
GB1193438A (en) Barbituric Acid Derivatives, preparation thereof and Pharmaceutical Compositions containing them

Legal Events

Date Code Title Description
PS Patent sealed
PE20 Patent expired after termination of 20 years

Effective date: 19930210